Navigation Links
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Date:6/10/2013

ater than those typically used with immediate-release amantadine.

About Levodopa-Induced Dyskinesia
Levodopa (also known as L-dopa) remains the gold standard for the treatment of the debilitating motor symptoms of Parkinson's disease.  An unfortunate side effect of prolonged treatment with levodopa is the occurrence of levodopa-induced dyskinesia (LID).  LID is characterized by involuntary non-purposeful movements of the head and neck, arms, legs or trunk.  With continued levodopa treatment, and as PD progresses, LID can become severely disabling and has been associated with a decrease in the quality of life for Parkinson's patients.1  LID affects approximately 30% of patients taking levodopa2, and is particularly problematic among young-onset Parkinson's disease patients.  There are currently no medications approved for the treatment of LID.  Reducing LID and improving "on time" without troublesome dyskinesia are among the greatest patient unmet medical needs in the treatment of advanced Parkinson's disease.3

About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals is dedicated to improving the lives of those affected by central nervous system (CNS) disorders by optimizing the pharmacokinetic profiles of approved drugs to create novel treatments for use alone and as components of fixed-dose combination products.  The Company is currently advancing a pipeline of aminoadamantane-based drug candidates for the treatment of Parkinson's disease, Alzheimer's disease, and other CNS disorders.  The Phase 2/3 EASED study investigating ADS-5102 (amantadine HCl extended release) for the treatment of levodopa-induced dyskinesia in Parkinson's disease has recently been completed.  MDX-8704 (memantine HCl ER/donepezil, US) and ADS-8704 (memantine HCl ER/donepezil, ex-US) are fixed-dose combination products in late-stage investigation for the treatment of dementia associated with
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimendaâ„¢
2. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
3. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
9. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... application process, CSA Medical, Inc. ( www.CSAmedical.com ) has ... future plans for its proprietary spray cryotherapy platform on ... will take place from 10:20-10:50 am at the Walter ... CSA Medical is first to harness the power of ...
... EMERYVILLE, Calif., Oct. 7 Onyx Pharmaceuticals, Inc. (Nasdaq: ... teleconference to provide a status update on its New Drug ... webcast of the presentation on our website at: ... 847-585-4405 and using the passcode 28119641. A replay of the ...
Cached Medicine Technology:CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference 2Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib 2
(Date:4/23/2014)... and Leisure Time Physical Activity on Mobility Limitation in ... increases the risk of mobility limitation in old age, ... found in a study which followed up 5,200 public ... at the Gerontology Research Center in Finland and the ... is often repetitive, wears the body and lasts for ...
(Date:4/23/2014)... as Ritalin, may prevent the depletion of self-control, according ... journal of the Association for Psychological Science. , Self-control ... trying to focus attention on a boring textbook are ... explanation for this difficulty: Exerting self-control for a long ... effectively on subsequent tasks. , "It is as if ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... the last few decades researchers have characterized a set ... and behavior in all types of species, from flies ... identified, but researchers surmise there are more. A team ... of Pennsylvania wondered if big-data approaches could find them. ... by John Hogenesch, PhD, professor of Pharmacology and first ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... a Million People Nationwide to take 10 Billion, Steps ... WASHINGTON, Sept. 17 More than 1,500 YMCAs ... active living and,healthy eating during "America On the Move ... partnership with the America On the Move,Foundation, aims to ...
... Science Series to Focus on Cardiovascular Disease, Prevention and Treatment Options, ... ... NEW YORK, Sept. 17 The upcoming episode of the "Charlie,Rose ... leading,global killers, which claims almost 900,000 lives each year in the United,States ...
... A new study by researchers at the University of Southern ... , Researchers found that a storyline on the primetime ... and healthy eating habits had a positive impact on the ... study, published in the Sept. 14 Journal of Health Communication ...
... cancer in the head and neck region may have ... without the disease, according to a report in the ... one of the JAMA/Archives journals. , Driving is a ... functions that work together. These functions can be compromised ...
... the Medicare,Quality Improvement Organization for Florida, is ... Laredo, Texas to provide free Diabetes,Empowerment Education ... 33,Florida counties. According to Kathleen Lightbourne, Project ... "The Program is designed to help,people with ...
... Open House - Saturday, October 20,Event to be held ... WEST PLAINS, Mo., Sept. 17 GAMMILL QUILTING ... systems, in,cooperation with it,s nationwide network of dealers, will ... 20. This event is being,held in honor of October,s ...
Cached Medicine News:Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 2Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 3Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 4Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 5Health News:Charlie Rose Science Series Explores Heart Disease 2Health News:Charlie Rose Science Series Explores Heart Disease 3Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:Medicare Every Diabetic Counts Project Gears Up for Kick-Off 2Health News:'Think Pink with Gammill(R)' 2
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... wide range of Platelet aggregometers allows ... meet particular needs. Single, dual and ... chart recorder outputs or digital computer ... Optical aggregometers, which measure platelet aggregation ...
... you in achieving improved cost efficiency ... to cut costs is constantly increasing. ... eliminate unnecessary manual interactions. Ensuring security ... control mechanisms like pipetting integrity check. ...
... Advia 2400 has minimal ... (as low as 2 ... (40 L/hour) thus maximizing ... universal rack handler facilitates ...
Medicine Products: